Prostate Cancer

Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.

Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Results from a retrospective study show that 177Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

Experts weigh in on the practical applications of PSMA PET imaging

Manojkumar Bupathi, MD, MS; Benjamin Garmezy, MD; Mike Lattanzi, MD, and x Damian N. Sorce, MD discuss how the practical applications of PSMA PET imaging, risk stratification, and evolving treatment strategies for advanced prostate cancer.

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.

SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.

Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

Following a positive meeting with the FDA, PT-112 is set to advance to a phase 3 trial for patients with metastatic castration-resistant prostate cancer.

Findings from prior studies, such as the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.

Beta emitters such as lutetium Lu 177 rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.